Persistent supravenous eruption induced by intravenous bortezomib therapy.
Mataix
J
J
Betlloch
I
I
Palmero
F
F
Romero
A
A
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D014652:Vascular Diseases / Q000139:chemically induced*; D014680:Veins / Q000187:drug effects
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib